Home・Lista de Ações・CareDx Inc

CareDx Inc

Fechado

SetorSaúde

45.3 -3.9

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

45.08

Máximo

47.14

Indicadores-chave
By Trading Economics
Rendimento	108M 111M
Vendas	14M 132M
P/E Médio do Setor	22.522 57.002
EPS	0.17
Margem de lucro	83.848
Funcionários	761
EBITDA	-3.8M 4.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+0.78% upside

Dividendos
By Acuity
Próximos Ganhos	3 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	557M 2.4B
Abertura anterior	49.2
Fecho anterior	45.3

Sentimento de Notícias

By Acuity

30%

70%

93 / 340 Ranking em Healthcare

CareDx Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de ago. de 2026, 19:36 UTC

CareDx Inc. shares are lower today, reflecting a slight decline since Tuesday's close, despite earlier rebounding from a session low.

11 de ago. de 2026, 23:41 UTC

CareDx Inc shares advanced in after-market trading, reflecting notable gains since Tuesday's close. The stock remains well above its 20-day moving average.

10 de ago. de 2026, 23:46 UTC

CareDx Inc shares are higher in after-market hours, trading significantly above their 20-day moving average and near the upper end of their one-month range.

7 de ago. de 2026, 20:06 UTC

CareDx Inc shares are higher today, recovering from an early dip. The stock has gained significantly since Thursday amid a decline in Treasury yields.

5 de ago. de 2026, 19:46 UTC

Shares of CareDx Inc. are lower today amid unusual volatility, reflecting a broader market sentiment influenced by disappointing employment data from ADP.

4 de ago. de 2026, 21:36 UTC

CareDx Inc shares are higher in after-market trading, reflecting a broader U.S. stock rally amid declining crude oil prices easing inflation concerns.

3 de ago. de 2026, 20:02 UTC

News

CareDx Inc shares rise following a rating upgrade to Buy from Craig-Hallum and a new price target of $64, up from $35.

31 de jul. de 2026, 23:06 UTC

News

CareDx shares are lower in after-market hours despite a 52% revenue increase to $132 million and raised full-year guidance to $490 million-$500 million.

30 de jul. de 2026, 23:41 UTC

News

CareDx Inc reported second-quarter revenue of $132 million, exceeding estimates. Following strong results and raised guidance, shares are higher in after-market trading.

29 de jul. de 2026, 19:56 UTC

CareDx Inc shares are lower, continuing a six-session decline amid rising crude oil prices and inflation concerns affecting broader market sentiment.

27 de jul. de 2026, 19:16 UTC

News

CareDx Inc is trading lower today, reflecting broader market trends amid declining oil prices and easing geopolitical tensions ahead of the Federal Reserve meeting.

22 de jul. de 2026, 19:16 UTC

CareDx Inc shares are lower today with no specific news identified. Broader market sentiment is affected by rising crude oil prices amid geopolitical tensions.

20 de jul. de 2026, 18:53 UTC

News

CareDx shares are lower as Director Valantine Hannah sold 28,779 shares at prices between $36.14 and $36.55, raising investor concerns.

Comparação entre Pares

Variação de preço

CareDx Inc Previsão

Preço-alvo

By TipRanks

0.78% parte superior

Previsão para 12 meses

Média 47.75 USD 0.78%

Máximo 64 USD

Mínimo 21 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para CareDx Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para CareDx Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

93 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.